Abstract
Summary
Generic drugs are essential in oncology because some anticancer drugs are only available as generics.
LPI (LP Information)' newest research report, the “Oncology Generic Injectable Drugs Industry Forecast” looks at past sales and reviews total world Oncology Generic Injectable Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Oncology Generic Injectable Drugs sales for 2023 through 2029. With Oncology Generic Injectable Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncology Generic Injectable Drugs industry.
This Insight Report provides a comprehensive analysis of the global Oncology Generic Injectable Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncology Generic Injectable Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oncology Generic Injectable Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncology Generic Injectable Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncology Generic Injectable Drugs.
The global Oncology Generic Injectable Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Oncology Generic Injectable Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oncology Generic Injectable Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oncology Generic Injectable Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oncology Generic Injectable Drugs players cover Teva Pharmaceutical, Pfizer, AstraZeneca, Roche, Eli Lilly, GlaxoSmithKline, Novartis, Mylan and Natco Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Generic Injectable Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Large Molecule Drugs
Small Molecule Drugs
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva Pharmaceutical
Pfizer
AstraZeneca
Roche
Eli Lilly
GlaxoSmithKline
Novartis
Mylan
Natco Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oncology Generic Injectable Drugs market?
What factors are driving Oncology Generic Injectable Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oncology Generic Injectable Drugs market opportunities vary by end market size?
How does Oncology Generic Injectable Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
LPI (LP Information)' newest research report, the “Oncology Generic Injectable Drugs Industry Forecast” looks at past sales and reviews total world Oncology Generic Injectable Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Oncology Generic Injectable Drugs sales for 2023 through 2029. With Oncology Generic Injectable Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncology Generic Injectable Drugs industry.
This Insight Report provides a comprehensive analysis of the global Oncology Generic Injectable Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncology Generic Injectable Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oncology Generic Injectable Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncology Generic Injectable Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncology Generic Injectable Drugs.
The global Oncology Generic Injectable Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Oncology Generic Injectable Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oncology Generic Injectable Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oncology Generic Injectable Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oncology Generic Injectable Drugs players cover Teva Pharmaceutical, Pfizer, AstraZeneca, Roche, Eli Lilly, GlaxoSmithKline, Novartis, Mylan and Natco Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Generic Injectable Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Large Molecule Drugs
Small Molecule Drugs
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva Pharmaceutical
Pfizer
AstraZeneca
Roche
Eli Lilly
GlaxoSmithKline
Novartis
Mylan
Natco Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oncology Generic Injectable Drugs market?
What factors are driving Oncology Generic Injectable Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oncology Generic Injectable Drugs market opportunities vary by end market size?
How does Oncology Generic Injectable Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oncology Generic Injectable Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oncology Generic Injectable Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oncology Generic Injectable Drugs by Country/Region, 2018, 2022 & 2029
2.2 Oncology Generic Injectable Drugs Segment by Type
2.2.1 Large Molecule Drugs
2.2.2 Small Molecule Drugs
2.3 Oncology Generic Injectable Drugs Sales by Type
2.3.1 Global Oncology Generic Injectable Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Oncology Generic Injectable Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Oncology Generic Injectable Drugs Sale Price by Type (2018-2023)
2.4 Oncology Generic Injectable Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Oncology Generic Injectable Drugs Sales by Application
2.5.1 Global Oncology Generic Injectable Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Oncology Generic Injectable Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oncology Generic Injectable Drugs Sale Price by Application (2018-2023)
3 Global Oncology Generic Injectable Drugs by Company
3.1 Global Oncology Generic Injectable Drugs Breakdown Data by Company
3.1.1 Global Oncology Generic Injectable Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Oncology Generic Injectable Drugs Sales Market Share by Company (2018-2023)
3.2 Global Oncology Generic Injectable Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Oncology Generic Injectable Drugs Revenue by Company (2018-2023)
3.2.2 Global Oncology Generic Injectable Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Oncology Generic Injectable Drugs Sale Price by Company
3.4 Key Manufacturers Oncology Generic Injectable Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oncology Generic Injectable Drugs Product Location Distribution
3.4.2 Players Oncology Generic Injectable Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oncology Generic Injectable Drugs by Geographic Region
4.1 World Historic Oncology Generic Injectable Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Oncology Generic Injectable Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oncology Generic Injectable Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oncology Generic Injectable Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Oncology Generic Injectable Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oncology Generic Injectable Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oncology Generic Injectable Drugs Sales Growth
4.4 APAC Oncology Generic Injectable Drugs Sales Growth
4.5 Europe Oncology Generic Injectable Drugs Sales Growth
4.6 Middle East & Africa Oncology Generic Injectable Drugs Sales Growth
5 Americas
5.1 Americas Oncology Generic Injectable Drugs Sales by Country
5.1.1 Americas Oncology Generic Injectable Drugs Sales by Country (2018-2023)
5.1.2 Americas Oncology Generic Injectable Drugs Revenue by Country (2018-2023)
5.2 Americas Oncology Generic Injectable Drugs Sales by Type
5.3 Americas Oncology Generic Injectable Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oncology Generic Injectable Drugs Sales by Region
6.1.1 APAC Oncology Generic Injectable Drugs Sales by Region (2018-2023)
6.1.2 APAC Oncology Generic Injectable Drugs Revenue by Region (2018-2023)
6.2 APAC Oncology Generic Injectable Drugs Sales by Type
6.3 APAC Oncology Generic Injectable Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oncology Generic Injectable Drugs by Country
7.1.1 Europe Oncology Generic Injectable Drugs Sales by Country (2018-2023)
7.1.2 Europe Oncology Generic Injectable Drugs Revenue by Country (2018-2023)
7.2 Europe Oncology Generic Injectable Drugs Sales by Type
7.3 Europe Oncology Generic Injectable Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oncology Generic Injectable Drugs by Country
8.1.1 Middle East & Africa Oncology Generic Injectable Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oncology Generic Injectable Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Oncology Generic Injectable Drugs Sales by Type
8.3 Middle East & Africa Oncology Generic Injectable Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oncology Generic Injectable Drugs
10.3 Manufacturing Process Analysis of Oncology Generic Injectable Drugs
10.4 Industry Chain Structure of Oncology Generic Injectable Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oncology Generic Injectable Drugs Distributors
11.3 Oncology Generic Injectable Drugs Customer
12 World Forecast Review for Oncology Generic Injectable Drugs by Geographic Region
12.1 Global Oncology Generic Injectable Drugs Market Size Forecast by Region
12.1.1 Global Oncology Generic Injectable Drugs Forecast by Region (2024-2029)
12.1.2 Global Oncology Generic Injectable Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oncology Generic Injectable Drugs Forecast by Type
12.7 Global Oncology Generic Injectable Drugs Forecast by Application
13 Key Players Analysis
13.1 Teva Pharmaceutical
13.1.1 Teva Pharmaceutical Company Information
13.1.2 Teva Pharmaceutical Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.1.3 Teva Pharmaceutical Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Teva Pharmaceutical Main Business Overview
13.1.5 Teva Pharmaceutical Latest Developments
13.2 Pfizer
13.2.1 Pfizer Company Information
13.2.2 Pfizer Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.2.3 Pfizer Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer Main Business Overview
13.2.5 Pfizer Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.3.3 AstraZeneca Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.4.3 Roche Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Eli Lilly
13.5.1 Eli Lilly Company Information
13.5.2 Eli Lilly Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.5.3 Eli Lilly Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly Main Business Overview
13.5.5 Eli Lilly Latest Developments
13.6 GlaxoSmithKline
13.6.1 GlaxoSmithKline Company Information
13.6.2 GlaxoSmithKline Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.6.3 GlaxoSmithKline Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 GlaxoSmithKline Main Business Overview
13.6.5 GlaxoSmithKline Latest Developments
13.7 Novartis
13.7.1 Novartis Company Information
13.7.2 Novartis Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.7.3 Novartis Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Novartis Main Business Overview
13.7.5 Novartis Latest Developments
13.8 Mylan
13.8.1 Mylan Company Information
13.8.2 Mylan Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.8.3 Mylan Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Mylan Main Business Overview
13.8.5 Mylan Latest Developments
13.9 Natco Pharma
13.9.1 Natco Pharma Company Information
13.9.2 Natco Pharma Oncology Generic Injectable Drugs Product Portfolios and Specifications
13.9.3 Natco Pharma Oncology Generic Injectable Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Natco Pharma Main Business Overview
13.9.5 Natco Pharma Latest Developments
14 Research Findings and Conclusion